PLTR News: Palantir Technologies rides higher as it is tasked with COVID-19 vaccine distribution
Premium|Take advantage of 50% OFF on your first month.
Start your subscription and get access to all our original articles.
You have reached your limit of 5 free articles for this month.
Get Premium without limits for only $9.99 for the first month
Access all our articles, insights, and analysts.
UNLOCK OFFER- NYSE:PLTR added 1.47% on Monday as the broader markets hovered around new all-time highs.
- Palantir is aiding the U.S. government for the continued distribution of vaccines.
- Yet another SPAC merger is revealed with Palantir as a chief investor.
NYSE:PLTR has started the week off on the right foot on the heels of another contract extension with the U.S. government. On Monday, shares of Palantir gained 1.47% to close the first trading session of the week at $22.13. The broader markets started the day slow, as investors weighed the monetary policy changes that may be announced later this week by the Federal Reserve. Still, all three major indices finished the day stronger, with the S&P 500 and the NASDAQ remaining near or at their all-time highs.
Stay up to speed with hot stocks' news!
Palantir announced on Monday that it will stay on with the U.S. Department of Health and Human Services to support COVID-19 vaccine distribution for another year. The data analytics giant created the software platform code-named Tiberius, to help with the coordination of vaccine distribution across the United States. Earlier in the rollout, the U.S. was ahead of the curve in terms of fully vaccinated citizens. Thanks to Palantir’s platform, the global distribution of U.S. produced vaccines can also be tracked, giving health authorities an idea of the current state of the pandemic.
PLTR stock forecast
Palantir’s recent interest in investing in SPAC mergers has been well documented, and the company may be ready to add another to its list. Ad-tech company AdTheorent is seeking a $1 billion SPAC merger deal with MCAP Acquisition Corp. AdTheorent uses machine learning and data science to allow for customers to optimize their marketing and advertising.
- NYSE:PLTR added 1.47% on Monday as the broader markets hovered around new all-time highs.
- Palantir is aiding the U.S. government for the continued distribution of vaccines.
- Yet another SPAC merger is revealed with Palantir as a chief investor.
NYSE:PLTR has started the week off on the right foot on the heels of another contract extension with the U.S. government. On Monday, shares of Palantir gained 1.47% to close the first trading session of the week at $22.13. The broader markets started the day slow, as investors weighed the monetary policy changes that may be announced later this week by the Federal Reserve. Still, all three major indices finished the day stronger, with the S&P 500 and the NASDAQ remaining near or at their all-time highs.
Stay up to speed with hot stocks' news!
Palantir announced on Monday that it will stay on with the U.S. Department of Health and Human Services to support COVID-19 vaccine distribution for another year. The data analytics giant created the software platform code-named Tiberius, to help with the coordination of vaccine distribution across the United States. Earlier in the rollout, the U.S. was ahead of the curve in terms of fully vaccinated citizens. Thanks to Palantir’s platform, the global distribution of U.S. produced vaccines can also be tracked, giving health authorities an idea of the current state of the pandemic.
PLTR stock forecast
Palantir’s recent interest in investing in SPAC mergers has been well documented, and the company may be ready to add another to its list. Ad-tech company AdTheorent is seeking a $1 billion SPAC merger deal with MCAP Acquisition Corp. AdTheorent uses machine learning and data science to allow for customers to optimize their marketing and advertising.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.